Chicago Capital
LGND icon

Chicago Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Chicago Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$172M Sell
551,225
-2,210
-0.4% -$653K 3.99% 6
2026
Q2 		$175M Sell
553,435
-8,240
-1% -$1.94M 4.21% 3
2026
Q1 		$112M Buy
561,675
+252
+0% +$49.9K 3.02% 9
2025
Q4 		$106M Sell
561,423
-7,188
-1% -$1.38M 2.62% 9
2025
Q3 		$101M Sell
568,611
-3,214
-0.6% -$478K 2.48% 11
2025
Q2 		$65M Buy
571,825
+17,308
+3% +$1.85M 1.6% 23
2025
Q1 		$58.3M Buy
554,517
+2,929
+0.5% +$331K 1.65% 27
2024
Q4 		$59.1M Buy
551,588
+5,767
+1% +$652K 1.57% 27
2024
Q3 		$54.6M Buy
545,821
+30,875
+6% +$3.11M 1.52% 29
2024
Q2 		$43.4M Buy
514,946
+285,350
+124% +$22.7M 1.29% 32
2024
Q1 		$16.8M Sell
229,596
-1,915
-0.8% -$141K 0.51% 45
2023
Q4 		$16.5M Sell
231,511
-128,834
-36% -$7.6M 0.6% 41
2023
Q3 		$21.6M Sell
360,345
-63,674
-15% -$4.19M 1.01% 35
2023
Q2 		$30.6M Sell
424,019
-25,489
-6% -$1.91M 1.38% 33
2023
Q1 		$33.1M Buy
449,508
+130,454
+41% +$9.27M 1.65% 30
2022
Q4 		$21.3M Sell
319,054
-417,228
-57% -$27.1M 1.18% 32
2022
Q3 		$39.6M Buy
736,282
+17,556
+2% +$1.03M 2.29% 15
2022
Q2 		$40M Sell
718,726
-69,496
-9% -$3.94M 2.21% 16
2022
Q1 		$55.3M Buy
788,222
+88,583
+13% +$6.43M 2.38% 11
2021
Q4 		$67.4M Sell
699,639
-6,135
-0.9% -$567K 2.51% 14
2021
Q3 		$61.3M Sell
705,774
-29,931
-4% -$2.31M 2.33% 15
2021
Q2 		$60.2M Buy
735,705
+16,540
+2% +$1.38M 2.35% 16
2021
Q1 		$68.4M Buy
719,165
+185,600
+35% +$17.5M 2.89% 6
2020
Q4 		$33.1M Sell
533,565
-245,240
-31% -$14M 1.48% 30
2020
Q3 		$46.3M Buy
778,805
+347,981
+81% +$23.7M 2.38% 18
2020
Q2 		$30.1M Buy
+430,824
New +$27.3M 1.74% 25

Other funds holding LGND

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Pembroke Management
Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Woodstock Corp
Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return
Isthmus Partners
Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return
Moody National Bank Trust Division
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Chicago Capital's LGND Position: Q3 2026 in Review

Chicago Capital reduced its Ligand Pharmaceuticals (LGND) stake by 0.4% in Q3 2026, selling an estimated $653K and leaving 551,225 shares worth $172M. The position accounts for 3.99% of the portfolio, ranked #6.

Chicago Capital first reported a position in LGND in Q2 2020 and has held it in 26 quarters since. The position peaked at $175M in Q2 2026. 109 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Chicago Capital held 551,225 shares of Ligand Pharmaceuticals worth $172M as of Q3 2026.
  • Chicago Capital sold 2,210 Ligand Pharmaceuticals shares in Q3 2026, an estimated $653K.
  • Ligand Pharmaceuticals made up 3.99% of Chicago Capital's portfolio in Q3 2026, its #6 holding.
  • Chicago Capital first reported a position in Ligand Pharmaceuticals in Q2 2020 and has held it in 26 quarters since.
  • Chicago Capital's Ligand Pharmaceuticals position peaked at $175M in Q2 2026.
  • 109 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Chicago Capital's 13F filing for Q3 2026, filed 13 Oct 2026.